CORONA Remedies Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from CORONA Remedies Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹136Over the last 3 years, every ₹100 of reported profit came with ₹136 of operating cash.
Higher than 65% of Healthcare companies in India.
Self-Funding Ratio
1.0×Over the last 3 years its own operating cash covered its investment spending (capex) 1.0 times.
Lower than 62% of Healthcare companies in India.
Cash Locked Ratio
₹6For every ₹100 of sales, ₹6 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹9 tied up three years earlier.
Less money tied up than 76% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹19Sales grew 59% in 3 years; of every extra ₹100 of sales, ₹19 became extra profit.
Higher than 55% of Healthcare companies in India.
Asset Productivity Ratio
+59% / +103%In 3 years sales changed by +59% while total assets changed by +103%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
1.6×Debt due within a year is covered 1.6 times by its yearly operating cash.
Higher than 55% of Healthcare companies in India.
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
78%Of every ₹100 the company owns, ₹78 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 84% of Healthcare companies in India.
Tangible Net Worth Ratio
65%Of every ₹100 of net worth, ₹65 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 83% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
CORONA Remedies Limited owes ₹0.38 for every ₹1 it owns. Net profit rose 24% in the year to Mar 2026, and grew 30% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
62.8Investors pay ₹62.8 for every ₹1 of CORONA Remedies Limited's yearly profit, higher than 79% of Healthcare companies in India.
P/B ratio
16.74The share price is 16.74 times CORONA Remedies Limited's book value per share, higher than 96% of Healthcare companies in India.
Net worth (book value)
₹747 CrWhat CORONA Remedies Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Return on equity (ROE)
26.6%CORONA Remedies Limited earned 26.6% on its shareholders' money over the last year, higher than 90% of Healthcare companies in India.
Owes vs Owns
0.38×CORONA Remedies Limited owes ₹0.38 for every ₹1 it owns (low), higher than 52% of Healthcare companies in India.
Dividend yield
0.49%CORONA Remedies Limited pays 0.49% of its share price as dividends a year, higher than 62% of dividend-paying Healthcare companies in India.
Revenue growth
+17%Revenue rose 17% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Profit growth
+24%Net profit rose 24% in the year to Mar 2026, and grew 30% a year on average over 3 years.
Profit margin
13.2%CORONA Remedies Limited keeps ₹13 of every ₹100 of revenue as net profit.
Cash quality
1.2×Cash from CORONA Remedies Limited's business was 1.2× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
56.1×CORONA Remedies Limited's operating profit covered its interest costs 56.1 times in the year to Mar 2026.
Cash vs debt
Net debtCORONA Remedies Limited had ₹163 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is CORONA Remedies Limited's P/E ratio?
Investors pay ₹62.8 for every ₹1 of CORONA Remedies Limited's yearly profit, higher than 79% of Healthcare companies in India.
What is CORONA Remedies Limited's return on equity?
CORONA Remedies Limited earned 26.6% on its shareholders' money over the last year, higher than 90% of Healthcare companies in India.
How much does CORONA Remedies Limited owe compared with what it owns?
CORONA Remedies Limited owes ₹0.38 for every ₹1 it owns (low), higher than 52% of Healthcare companies in India.
Does CORONA Remedies Limited pay a dividend?
Yes. CORONA Remedies Limited pays 0.49% of its share price as dividends a year, higher than 62% of dividend-paying Healthcare companies in India.
Is CORONA Remedies Limited's revenue growing?
Revenue rose 17% in the year to Mar 2026, and grew 17% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.